Clinical trials: Lipemia
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Hypertension, Hyperlipidemia
The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians
In this randomized controlled trial, we will provide primary care physicians with free samples of highly effective generic cardiovascular medications.
- Trial name
- SAMPLES (NCT00761904)
- Testing
- Free Generic Samples (hydrochlorothiazide, simvastatin)
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Hyperlipidemia
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255458
- Testing
- AK102
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Akeso
Hypercholesteremia
Phytosterol Supplementation and Cardiovascular Risk
This study examined the effects of 2.6 g/d of phytosterol ingestion on LDL cholesterol metabolism. It is expected that this dose will significantly reduce LDL cholesterol after 12 weeks of supplementation.
- Trial name
- NCT00153738
- Testing
- phytosterol
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Cooper Institute
HIV Infections, Hyperlipidemia
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
The purpose of this research is to study the effects of rosiglitazone, a drug usually taken for Type II diabetes, on HIV-associated hyperlipidemia.
- Trial name
- NCT00006493
- Testing
- Rosiglitazone
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Hypercholesterolemia
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic
This study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of DC739 after multiple-dose oral administration, to explore the clinical effective dose, and to initially explore the efficacy and safety in…
- Trial name
- NCT04927221
- Testing
- DC371739 Tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Hypertension
Effect of Amlodipine on the Lipid Profile of Newly Diagnosed Hypertensive Patients
In this study, Amlodipine has been used to study its effects in newly diagnosed hypertensive patients.
- Conditions
- Hypercholesterolemia, Hypertension, Cholesterol Deposition
- Trial name
- NCT05467384
- Testing
- Amlodipine
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ayub Teaching Hospital
Hypercholesterolaemia
A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
This is a first-in-human,randomized, double-blind, placebo-controlled, single dose escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of AK102 administered subcutaneously in healthy subjects.
- Trial name
- NCT04169386
- Testing
- AK102
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Akeso
Metabolic Syndrome, Familial Hypertriglyceridemia
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma triglyceride concentrations and improves hepatic…
- Conditions
- Metabolic Syndrome, Familial Hypertriglyceridemia, Familial Combined Hyperlipidemia
- Trial name
- NCT00465751
- Testing
- chenodeoxycholic acid
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hypercholesterolemia, Hyperlipidemia
Effect of MK0524A on Cholesterol Levels (0524A-048)
The primary objective of the study is to assess the effects of MK0524A in reducing cholesterol levels in an Asian population.
- Trial name
- NCT00536510
- Testing
- laropiprant/niacin (MK0524A)
- Volunteers
- 646 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon like peptide 1) reduces intestinal production of lipoprotein particles.
- Trial name
- NCT01600703
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of treatment in…
- Trial name
- NCT01288469
- Testing
- Alirocumab, Atorvastatin
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sanofi
Hyperlipidemia
Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C
Coronary heart disease (CHD) is the single leading cause of death in the United States . Serum Cholesterol is known to have a direct impact on a number of human diseases through a variety of mechanisms.
- Trial name
- NCT00525083
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Vanderbilt University Medical Center
Social Determinants of Health (SDOH), Hypertension
Arizona CEAL: Linking Social Care With Healthcare Systems to Address SDOH
The goal of the Arizona Community Engagement Alliance (AZ-CEAL) will be to combine social care with healthcare programs. The study will be connecting selected patients from clinics with trained community health workers (CHW) who…
- Conditions
- Social Determinants of Health (SDOH), Hypertension, Diabetes Mellitus, Hypercholesterolaemia
- Trial name
- AZCEAL (NCT07799961)
- Testing
- Community Health Worker intervention, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 740 people, healthy volunteers welcome
- Sponsor
- Sairam Parthasarathy
Homozygous Familial Hypercholesterolemia
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.
- Trial name
- NCT04031742
- Testing
- IBI306
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hyperlipidemia, Hypercholesterolemia
Genetic Influence on Statin Pharmacodynamics
The study intends to investigate whether genetics influence how individuals respond to statins (clinical outcomes and changes in carotid intimal media thickness)
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT01569854
- Where
- United States
- Sponsor
- Ohio State University
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Hypertriglyceridemia
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.
- Trial name
- NCT03693131
- Testing
- Icosapent (MND-2119), Icosapent (EPADEL CAPSULES 300)
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.